Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ESAM Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESAM, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Docetaxel polymeric micelle Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Docetaxel polymeric micelle: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ERVW-1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ERVW-1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP.
8 min read
ERVV-2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ERVV-2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ERVV-1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ERVV-1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
TBR-065 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
TBR-065: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ERVMER34-1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ERVMER34-1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
NS-041 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
NS-041: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALOX15B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALOX15B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
CYP-001: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALOX5AP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALOX5AP, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.